دورية أكاديمية
Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.
العنوان: | Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications. |
---|---|
المؤلفون: | Rezaei Z; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.; Chemical Engineering Department, Sharif University of Technology, Azadi Ave, Tehran 11365-11155, Iran., Yilmaz-Aykut D; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.; Department of Chemical Engineering, Faculty of Engineering, Istanbul University-Cerrahpaşa, 34320 Istanbul, Turkey., Tourk FM; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.; Department of Mechanical Engineering, Northeastern University, Boston, MA 02115, USA., Bassous N; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA., Barroso-Zuppa M; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.; School of Medicine and Health Sciences, Tecnologico de Monterrey, Mexico City 14380, Mexico., Shawl AI; Department of Biology, College of Arts and Sciences, Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates., Ashraf SS; Department of Biology, College of Arts and Sciences, Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.; Center for Biotechnology (BTC), Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.; Center for Catalysis and Separation (CeCas), SAN Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.; Advanced Materials Chemistry Centre (AMCC), SAN Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates., Avci H; Department of Metallurgical and Materials Engineering, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey.; Cellular Therapy and Stem Cell Research Center, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey.; Translational Medicine Research and Clinical Center, Eskisehir Osmangazi University, 26040 Eskisehir, Turkey., Hassan S; Division of Engineering in Medicine, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Cambridge, MA 02139, USA.; Department of Biology, College of Arts and Sciences, Main Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.; Advanced Materials Chemistry Centre (AMCC), SAN Campus, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates. |
المصدر: | Pharmaceutics [Pharmaceutics] 2022 Oct 21; Vol. 14 (10). Date of Electronic Publication: 2022 Oct 21. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
مستخلص: | Non-targeted persistent immune activation or suppression by different drug delivery platforms can cause adverse and chronic physiological effects including cancer and arthritis. Therefore, non-toxic materials that do not trigger an immunogenic response during delivery are crucial for safe and effective in vivo treatment. Hydrogels are excellent candidates that can be engineered to control immune responses by modulating biomolecule release/adsorption, improving regeneration of lymphoid tissues, and enhancing function during antigen presentation. This review discusses the aspects of hydrogel-based systems used as drug delivery platforms for various diseases. A detailed investigation on different immunomodulation strategies for various delivery options and deliberate upon the outlook of such drug delivery platforms are conducted. |
References: | Membranes (Basel). 2021 Sep 13;11(9):. (PMID: 34564519) Trends Immunol. 2006 Oct;27(10):470-6. (PMID: 16920025) N Engl J Med. 2019 Aug 15;381(7):603-613. (PMID: 31180194) Biomaterials. 2019 Nov;220:119403. (PMID: 31401468) Biomaterials. 2020 May;240:119841. (PMID: 32088411) Small. 2019 Sep;15(36):e1902232. (PMID: 31328877) Front Cardiovasc Med. 2019 Mar 21;6:26. (PMID: 30949485) J Immunol. 2017 Dec 1;199(11):3721-3730. (PMID: 29158348) Sci Adv. 2022 Feb 25;8(8):eabd8056. (PMID: 35213226) Trends Mol Med. 2020 Jul;26(7):649-669. (PMID: 32371171) N Engl J Med. 2018 Jan 4;378(1):35-47. (PMID: 29298160) Exp Mol Med. 2018 Dec 13;50(12):1-11. (PMID: 30546008) Carbohydr Polym. 2022 Jul 1;287:119336. (PMID: 35422300) Cells. 2020 Feb 12;9(2):. (PMID: 32059502) Nat Rev Cancer. 2019 Oct;19(10):587-602. (PMID: 31492927) Chem Rev. 2021 Sep 22;121(18):11305-11335. (PMID: 34415742) J Nanobiotechnology. 2022 May 14;20(1):232. (PMID: 35568914) Adv Healthc Mater. 2019 Apr;8(8):e1801578. (PMID: 30714328) Discov Med. 2011 Apr;11(59):293-301. (PMID: 21524383) Lancet. 2011 Jul 23;378(9788):319-27. (PMID: 21714999) Nat Mater. 2020 Jan;19(1):118-126. (PMID: 31427744) Biomaterials. 2010 Apr;31(12):3166-74. (PMID: 20138358) Bioeng Transl Med. 2017 May 16;2(2):139-155. (PMID: 28932817) Tissue Eng Part A. 2013 Jun;19(11-12):1465-75. (PMID: 23432371) Clin Colorectal Cancer. 2019 Dec;18(4):e349-e360. (PMID: 31351862) Acta Biomater. 2019 Jun;91:186-194. (PMID: 31028910) Protein Cell. 2018 Jan;9(1):135-139. (PMID: 28488247) Sci Rep. 2019 Apr 25;9(1):6535. (PMID: 31024011) Adv Drug Deliv Rev. 2017 May 15;114:161-174. (PMID: 28532690) Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10287-92. (PMID: 12122211) Commun Biol. 2019 Oct 25;2:392. (PMID: 31667366) Biomaterials. 2021 Jan;268:120549. (PMID: 33278685) Anal Chem. 2017 Jan 3;89(1):276-299. (PMID: 28105839) Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2:S101-16. (PMID: 18308998) Adv Sci (Weinh). 2021 Apr 09;8(10):2003599. (PMID: 34026440) Int J Nanomedicine. 2019 Feb 20;14:1311-1333. (PMID: 30863063) Nat Mater. 2015 Jun;14(6):643-51. (PMID: 25985456) RSC Adv. 2019 Jul 10;9(37):21396-21404. (PMID: 35521319) Acta Biomater. 2021 Apr 1;124:179-190. (PMID: 33524560) Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9864-9. (PMID: 12114532) Nat Mater. 2018 Jun;17(6):484-498. (PMID: 29784994) Int J Mol Sci. 2020 Feb 26;21(5):. (PMID: 32111075) Tissue Eng Part B Rev. 2019 Dec;25(6):492-499. (PMID: 31436142) Trends Biotechnol. 2016 Jun;34(6):470-482. (PMID: 27138899) Hum Vaccin Immunother. 2016 May 3;12(5):1092-101. (PMID: 26889818) Bioact Mater. 2017 Sep 06;3(1):118-128. (PMID: 29744449) J Control Release. 2017 Jun 10;255:81-93. (PMID: 28408199) Adv Mater. 2021 Oct;33(39):e2100176. (PMID: 34251690) Adv Drug Deliv Rev. 2021 Jul;174:87-113. (PMID: 33484736) Molecules. 2019 Feb 08;24(3):. (PMID: 30744011) Curr Opin Organ Transplant. 2014 Dec;19(6):610-5. (PMID: 25304813) Methods Enzymol. 2006;420:391-409. (PMID: 17161708) Theranostics. 2019 Oct 16;9(25):7906-7923. (PMID: 31695807) ACS Biomater Sci Eng. 2020 Mar 9;6(3):1614-1629. (PMID: 33455368) Ther Adv Med Oncol. 2015 Mar;7(2):85-96. (PMID: 25755681) Macromol Biosci. 2022 Jun;22(6):e2200043. (PMID: 35332672) J Hematol Oncol. 2019 Nov 28;12(1):126. (PMID: 31779642) Adv Healthc Mater. 2016 Nov;5(22):2841-2855. (PMID: 27709832) Acta Biomater. 2019 Apr 1;88:15-31. (PMID: 30771535) J Immunol. 2005 Sep 1;175(5):3309-17. (PMID: 16116223) Immunology. 2018 Oct;155(2):186-201. (PMID: 29908065) J Immunol. 2014 Nov 15;193(10):4988-99. (PMID: 25305313) Adv Drug Deliv Rev. 2018 Mar 1;127:138-166. (PMID: 29626550) Biomed Res Int. 2020 Dec 28;2020:8868618. (PMID: 33778064) ACS Biomater Sci Eng. 2020 Jun 8;6(6):3270-3274. (PMID: 33463163) Thromb Haemost. 2006 Mar;95(3):499-510. (PMID: 16525579) Mater Sci Eng C Mater Biol Appl. 2020 Oct;115:111096. (PMID: 32600700) Biomaterials. 2020 Oct;256:120216. (PMID: 32736171) Curr Pharm Des. 2017;23(18):2623-2643. (PMID: 28201972) Nano Today. 2021 Feb;36:. (PMID: 33425002) J Biomed Mater Res A. 2007 Dec 1;83(3):585-96. (PMID: 17503526) Curr Opin Immunol. 1996 Jun;8(3):355-61. (PMID: 8793992) J Gene Med. 2022 May;24(5):e3415. (PMID: 35132731) Biomaterials. 2021 Feb;269:120608. (PMID: 33388690) Front Bioeng Biotechnol. 2020 Apr 07;8:292. (PMID: 32318563) Biomaterials. 2022 Jan;280:121272. (PMID: 34864428) Nat Nanotechnol. 2021 Jul;16(7):748-759. (PMID: 34211166) ACS Biomater Sci Eng. 2018 Apr 9;4(4):1241-1250. (PMID: 29682605) Adv Drug Deliv Rev. 2016 Mar 1;98:86-98. (PMID: 26546466) Ann N Y Acad Sci. 2006 Oct;1079:340-4. (PMID: 17130576) JAMA Netw Open. 2021 Jul 1;4(7):e2118811. (PMID: 34323983) Front Pharmacol. 2014 May 27;5:123. (PMID: 24904424) Oncotarget. 2018 Apr 03;9(25):17675-17688. (PMID: 29707140) Annu Rev Med. 2014;65:185-202. (PMID: 24188664) Nat Biotechnol. 2012 Dec;30(12):1217-24. (PMID: 23159881) Biomaterials. 2009 Oct;30(28):4907-14. (PMID: 19560813) Front Bioeng Biotechnol. 2020 Jun 05;8:542. (PMID: 32582667) J Biomed Mater Res B Appl Biomater. 2022 Feb;110(2):265-288. (PMID: 34318595) Sci Adv. 2021 Jan 6;7(2):. (PMID: 33523973) Trends Immunol. 2003 Sep;24(9):500-7. (PMID: 12967674) Front Cell Infect Microbiol. 2020 Jan 29;10:8. (PMID: 32064239) EXCLI J. 2020 Mar 09;19:334-350. (PMID: 32256272) Mater Today Bio. 2021 Sep 21;12:100139. (PMID: 34632363) Molecules. 2020 Mar 27;25(7):. (PMID: 32230990) J Am Chem Soc. 2021 Oct 20;143(41):17180-17190. (PMID: 34636555) Front Immunol. 2017 Nov 29;8:1676. (PMID: 29238347) J Immunol. 2005 Mar 1;174(5):3006-14. (PMID: 15728514) J Control Release. 2015 Dec 10;219:155-166. (PMID: 26264833) Adv Exp Med Biol. 2009;666:95-107. (PMID: 20054978) J Biomed Mater Res A. 2020 May;108(5):1159-1170. (PMID: 31990447) Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. (PMID: 23690610) IEEE Trans Biomed Eng. 2014 May;61(5):1474-81. (PMID: 24759280) Mol Ther. 2018 Sep 5;26(9):2087-2106. (PMID: 30107997) Adv Mater. 2014 Oct;26(38):6530-41. (PMID: 25155610) Langmuir. 2019 Feb 5;35(5):1837-1845. (PMID: 30086636) ACS Nano. 2018 Mar 27;12(3):2283-2291. (PMID: 29529366) Adv Healthc Mater. 2021 Jan;10(1):e2001239. (PMID: 32935937) Front Endocrinol (Lausanne). 2021 Aug 17;12:716692. (PMID: 34484126) Theranostics. 2020 Jan 1;10(2):725-740. (PMID: 31903147) J Diabetes Sci Technol. 2009 Mar 01;3(2):320-30. (PMID: 20144363) BMC Biol. 2012 Jan 31;10:7. (PMID: 22293401) |
فهرسة مساهمة: | Keywords: biomaterials; foreign body response; hydrogels; immune modulation; tissue engineering |
تواريخ الأحداث: | Date Created: 20221027 Latest Revision: 20221030 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9610165 |
DOI: | 10.3390/pharmaceutics14102244 |
PMID: | 36297679 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1999-4923 |
---|---|
DOI: | 10.3390/pharmaceutics14102244 |